Почетна › Trostruko negativni rak dojke › Merilend
Kliničke studije za Trostruko negativni rak dojke u državi Merilend
17 studija za Trostruko negativni rak dojke traži učesnike na lokacijama u državi Merilend.
Gradovi u državi Merilend
Zvanični tekst studije (na engleskom)
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесникОпсервациона студија
Узраст од 18 до 120 · Оба пола · Ажурирано 13. 11. 2026. · NCT07619534Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03606967A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- MedStar Franklin Square Medical Center ( Site 0031), Baltimore
- MedStar Good Samaritan Hospital ( Site 0079), Baltimore
- MedStar Southern Maryland Hospital Center ( Site 0100), Clinton
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06841354A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Mercy Medical Center - Baltimore ( Site 0015), Baltimore
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 10. 11. 2026. · NCT06966700Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Holy Cross Hospital ( Site 0069), Silver Spring
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT06393374Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Sinai Hospital of Baltimore, Inc., Baltimore
- St. Agnes Hospital, Baltimore
- Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
- и још 2
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05633654Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- USOR Maryland Oncology Hematology, Rockville
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
- United Theranostics, Glen Burnie
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 8. 10. 2026. · NCT07311993Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT07340541A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
- United Theranostics, Glen Burnie
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT07020117PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 3. 9. 2026. · NCT06245889A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
- National Institutes of Health Clinical Center, Bethesda
Тражи се учесник
Узраст од 18 до 120 · Оба пола · Ажурирано 21. 8. 2026. · NCT07067138A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Local Institution - 1035, Baltimore
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 10. 8. 2026. · NCT06926868Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Frederick Health Hospital, Frederick
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 29. 6. 2026. · NCT07327489Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
- National Institute of Health Clinical Center, Bethesda
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 6. 2026. · NCT05660083A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2025. · NCT05902988First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 28. 11. 2022. · NCT05627960Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.